Amsterdam, December 6, 2006 -- Elsevier, a world-leading healthcare and scientific publisher, announced today new features for its drug tracking and analysis tool, Inteleos. These features enable users to search drug records by Mechanism of Action and Drug Class, graphically chart competitor drugs using a new analysis tool, and search and review clinical trial reports from ClinicalTrials.gov. Users can increase productivity and improve results by specifically tailoring information to meet their business needs.
By indexing Mechanism of Action terms and creating a searchable Drug Class field, Inteleos increases the flexibility of its search and analysis features. The Competitive Grid analysis tool graphically charts competitor drugs per therapy area and allows for comparisons by mechanism of action or drug class, creating dynamic results instantly. Using information reported by ClinicalTrials.gov users can identify and analyze clinical trials across industry, government and academia. Users can also view key trial details specific to drug records.
"Our team continues to show real commitment to customer focus. Improvements made to Inteleos are based on industry feedback; users tell us what they need - the type of information and the format - to improve their business decision-making and we strive to meet these needs" says Julie Gordon, Director of Inteleos, Elsevier. "The inclusion of the Drug Class feature enhances the flexibility and breadth of searching and analysis possible and this is actualized by the Competitor Grid analysis tool. Trial information, via ClinicalTrials.gov, further expands our service into the clinical environment and is the starting point for future enhancements, as customers tell us this is an area of critical need."
In the coming months, Inteleos will enhance services for BizInt customers by enabling the export of Inteleos data into BizInt Smart Charts.
Inteleos provides business intelligence support to professionals working in or providing services to the pharmaceutical and biotech industries. Inteleos tracks drug development and associated licensing activities from late-stage preclinical through to launch and post-marketing studies. In addition to critical drug development information, Inteleos provides easy-to-use analysis tools to support decision-making and drive strategy. Inteleos is powered by AdvanTechnologies, Inc.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.